Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABFRA:61MA -0.22%91 EBIT per Share is €2.05 as of Mar. 2026. GuruFocus rates FRA:61MA with a GF Score™ of 91/100 and a GF Value™ of €50.10 (Fairly Valued). Among 687 Medical Devices & Instruments companies, MedCap AB ranks better than 70.31% on this metric.
MedCap AB's EBIT per Share for the
three
months ended in Mar. 2026 was €0.52.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €2.05.
During the past 12 months, the average EBIT per Share Growth Rate of MedCap AB was 20.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 24.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 29.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 36.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for MedCap AB's EBIT per Share or its related term are showing as below:
FRA:61MA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -61.8 Med: 24 Max: 254.5
Current: 24.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of MedCap AB was 254.50% per year. The lowest was -61.80% per year. And the median was 24.00% per year.
FRA:61MA's 3-Year EBIT Growth Rate is ranked better than 70.31% of 687
companies
in the Medical Devices & Instruments industry
Industry Median: 9.1
vs FRA:61MA: 24.10
MedCap AB's EBIT for the
three
months ended in Mar. 2026 was €7.8 Mil.
MedCap AB (FRA:61MA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
MedCap AB EBIT per Share Related Terms
MedCap AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for MedCap AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedCap AB (FRA:61MA) has a EBIT per Share of €2.05 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on MedCap AB and its competitors. According to the industry distribution chart, MedCap AB ranks #204 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 29.7%.
Is MedCap AB's EBIT per Share too high?
MedCap AB's current EBIT per Share is €2.05. Based on the distribution chart, MedCap AB ranks #204 out of 687 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MedCap AB has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #204 out of 687 companies for EBIT per Share. This puts MedCap AB in the upper half of its industry. The industry median EBIT per Share is 9.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.10, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current EBIT per Share is €2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (FRA:61MA) is currently considered Fairly Valued. The stock's GF Value™ is €50.10, compared to a current price of €45.54 — trading 9.1% below its estimated fair value. The current EBIT per Share is €2.05. MedCap AB's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For MedCap AB (FRA:61MA), the current EBIT per Share is €2.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (FRA:61MA) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of €45.54 is trading 9.1% below its estimated GF Value™ of €50.10.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for FRA:61MA:
EBIT per Share: €2.05
GF Value™: €50.10 vs. price of €45.54 (9.1% below fair value)
No single metric tells the full story. See the FRA:61MA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
91GF Score
Get the complete analysis for FRA:61MA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61MA has been successfully added to your 
